Literature DB >> 26153649

Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.

Ammad Ahmad Farooqi1, Zahid H Siddik2.   

Abstract

Platelet-derived growth factor (PDGF)-mediated signalling has emerged as one of the most extensively and deeply studied biological mechanism reported to be involved in regulation of growth and survival of different cell types. However, overwhelmingly increasing scientific evidence is also emphasizing on dysregulation of spatio-temporally controlled PDGF-induced signalling as a basis for cancer development. We partition this multi-component review into recently developing understanding of dysregulation PDGF signalling in different cancers, how PDGF receptors are quantitatively controlled by microRNAs. Moreover, we also summarize most recent advancements in therapeutic targeting of PDGFR as evidenced by preclinical studies. Better understanding of the PDGF-induced intracellular signalling in different cancers will be helpful in catalysing the transition from a segmented view of cancer biology to a conceptual continuum.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  PDGF; apoptosis; cancer; miRNA; signalling

Mesh:

Substances:

Year:  2015        PMID: 26153649      PMCID: PMC5289298          DOI: 10.1002/cbf.3120

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  63 in total

1.  Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression.

Authors:  Wenling Wang; Lifeng Qi; Minhan Tan; Zhenting Zhang; Ju Du; Xiaona Wei; Xin Yao
Journal:  Urol Oncol       Date:  2015-03-09       Impact factor: 3.498

2.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Authors:  David Akhavan; Alexandra L Pourzia; Alex A Nourian; Kevin J Williams; David Nathanson; Ivan Babic; Genaro R Villa; Kazuhiro Tanaka; Ali Nael; Huijun Yang; Julie Dang; Harry V Vinters; William H Yong; Mitchell Flagg; Fuyuhiko Tamanoi; Takashi Sasayama; C David James; Harley I Kornblum; Tim F Cloughesy; Webster K Cavenee; Steven J Bensinger; Paul S Mischel
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

3.  The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.

Authors:  M Juliachs; C Muñoz; C A Moutinho; A Vidal; E Condom; M Esteller; M Graupera; O Casanovas; J R Germà; A Villanueva; F Viñals
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

4.  MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.

Authors:  Michela Garofalo; Young-Jun Jeon; Gerard J Nuovo; Justin Middleton; Paola Secchiero; Pooja Joshi; Hansjuerg Alder; Natalya Nazaryan; Gianpiero Di Leva; Giulia Romano; Melissa Crawford; Patrick Nana-Sinkam; Carlo M Croce
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

5.  miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma.

Authors:  Jelena Põlajeva; Fredrik J Swartling; Yiwen Jiang; Umashankar Singh; Kristian Pietras; Lene Uhrbom; Bengt Westermark; Pernilla Roswall
Journal:  BMC Cancer       Date:  2012-08-29       Impact factor: 4.430

6.  PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation.

Authors:  Oana Mihaela Tudoran; Olga Soritau; Loredana Balacescu; Laura Pop; Guillaume Meurice; Simona Visan; Staffan Lindberg; Alexandru Eniu; Ulo Langel; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  J Cell Mol Med       Date:  2014-10-14       Impact factor: 5.310

7.  The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.

Authors:  Yingying Shen; Xiaoke Shi; Jingxuan Pan
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

Review 8.  Targeting the PDGF signaling pathway in tumor treatment.

Authors:  Carl-Henrik Heldin
Journal:  Cell Commun Signal       Date:  2013-12-20       Impact factor: 5.712

9.  Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Authors:  Osamu Tohyama; Junji Matsui; Kotaro Kodama; Naoko Hata-Sugi; Takayuki Kimura; Kiyoshi Okamoto; Yukinori Minoshima; Masao Iwata; Yasuhiro Funahashi
Journal:  J Thyroid Res       Date:  2014-09-10

10.  Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.

Authors:  Jordi Rubió-Casadevall; Joan Lluis Borràs; Maria Carme Carmona-García; Alberto Ameijide; Allan Gonzalez-Vidal; Maria Rosa Ortiz; Ramon Bosch; Francesc Riu; David Parada; Esther Martí; Josefina Miró; Juan Jose Sirvent; Jaume Galceran; Rafael Marcos-Gragera
Journal:  World J Surg Oncol       Date:  2015-02-13       Impact factor: 2.754

View more
  40 in total

1.  A Novel Endogenous Damage Signal, CSF-2, Activates Multiple Beneficial Functions of Adipose Tissue-Derived Mesenchymal Stem Cells.

Authors:  Se-Ra Park; Ara Cho; Jae-Wan Kim; Hwa-Yong Lee; In-Sun Hong
Journal:  Mol Ther       Date:  2019-03-19       Impact factor: 11.454

2.  Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.

Authors:  Yulian Mytsyk; Serhiy Pasichnyk; Ihor Dutka; Ihor Dats; Dmytro Vorobets; Michał Skrzypczyk; Yerzhan Uteuliyev; Andrea Botikova; Katarina Gazdikova; Peter Kubatka; Peter Urdzik; Peter Kruzliak
Journal:  Clin Exp Med       Date:  2020-02-05       Impact factor: 3.984

Review 3.  Rab23 activities and human cancer-emerging connections and mechanisms.

Authors:  Yanan Chen; Fanny Ng; Bor Luen Tang
Journal:  Tumour Biol       Date:  2016-07-23

Review 4.  MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Authors:  Michele Ghidini; Jens C Hahne; Melissa Frizziero; Gianluca Tomasello; Francesco Trevisani; Andrea Lampis; Rodolfo Passalacqua; Nicola Valeri
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

5.  The rise of soluble platelet-derived growth factor receptor β in CSF early after subarachnoid hemorrhage correlates with cerebral vasospasm.

Authors:  Jing-Peng Liu; Zhen-Nan Ye; Sheng-Yin Lv; Zong Zhuang; Xiang-Sheng Zhang; Xin Zhang; Wei Wu; Lei Mao; Yue Lu; Ling-Yun Wu; Jie-Mei Fan; Wen-Ju Tian; Chun-Hua Hang
Journal:  Neurol Sci       Date:  2018-04-10       Impact factor: 3.307

Review 6.  Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.

Authors:  Melinda D Wu; Javid J Moslehi; Jonathan R Lindner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-04       Impact factor: 8.311

Review 7.  Recent developments in receptor tyrosine kinases targeted anticancer therapy.

Authors:  Samir H Raval; Ratn D Singh; Dilip V Joshi; Hitesh B Patel; Shailesh K Mody
Journal:  Vet World       Date:  2016-01-29

8.  Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients.

Authors:  Ilaria Marech; Michele Ammendola; Rosario Sacco; Giuseppe Sammarco; Valeria Zuccalà; Nicola Zizzo; Christian Leporini; Maria Luposella; Rosa Patruno; Gianfranco Filippelli; Emilio Russo; Mariangela Porcelli; Cosmo Damiano Gadaleta; Giovambattista De Sarro; Girolamo Ranieri
Journal:  J Cell Mol Med       Date:  2016-04-22       Impact factor: 5.310

Review 9.  Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.

Authors:  Wagner Ricardo Montor; Andrei Ronaldo Oliveira Silva Escartin Salas; Fabiana Henriques Machado de Melo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

Review 10.  Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.

Authors:  Domenica Musumeci; Chiara Platella; Claudia Riccardi; Federica Moccia; Daniela Montesarchio
Journal:  Cancers (Basel)       Date:  2017-12-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.